DMD and Duchenne muscular dystrophy: Investigational therapeutics for DMD have historically fallen short in clinical trials (15), highlighting both the complexity of the pathophysiological milieu that drives degeneration of dystrophin-deficient muscles and disparity between the human condition and animal models.